Navigation Links
DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
Date:1/29/2009

on at early stage in France and in Europe, and that shares our business vision and values the potential of our drug development based on our unique proprietary siDNA technology. This financing will allow DNA Therapeutics to move ahead with an aggressive timeline for the preclinical development of Dbait which will enter into phase I/II clinical trial by the end of 2010."

"Since January 2006, we have been carrying out fundamental work consisting of creating and shaping our company portfolio to meet SEFTI's objectives. This effort has resulted in an original portfolio companies, mainly in France and Switzerland, close to clinical stage, and attractive to big biotech, pharmaceutical and medical device companies. Adding DNA Therapeutics, which develops a breakthrough treatment in oncology, to SEFTI's portfolio companies, is in line with our innovative investment strategy. Today, SGAM SEFTI has already invested, or is ready to invest in near term, more than half of the fund's commitments," said Beatrice Denys, manager of the fund. "The life of the fund is entering a second phase in which one of our priorities will be to endeavor to demonstrate the validity of our investment choices, notably through the emphasis placed on organizing output," added Eric Viaud, exclusive advisor of SEFTI.

About DNA Therapeutics

DNA Therapeutics SA (http://www.dna-therapeutics.com) headquartered in the Genopole biocluster (Evry, France) was founded in June 2006. Its original siDNA technology consists in interfering with DNA repair pathways that cancer cells use to resist radiotherapy and chemotherapy. Its lead product, Dbait, will be first administered locally in combination with radiotherapy in selected indications where radiotherapy is used as standard of care but fails due to radio-resistance. After its first clinical validation, the systemic administration of Dbait
'/>"/>

SOURCE DNA Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
2. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
3. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
7. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
8. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
9. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
10. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
11. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
(Date:8/21/2014)... , Aug. 21, 2014  IBM (NYSE: IBM ... ( DESY ), a leading national research center in ... and storage of massive volumes of x-ray data. The ... on IBM software defined technology can handle more than ... and help scientists worldwide gain faster insights into the ...
(Date:8/21/2014)... , Aug. 21, 2014  Seventy-one percent of Americans believe ... is a serious public health and safety issue in ... a survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication abuse ... with this very serious health situation facing our country," ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... , , , ... the leader in the development of devices for the percutaneous ... group of patients with the MitraClip((R)) system at the Elisabethinen ... device commercially available in the European Union which provides a ...
... HERNDON, Va., Sept. 8 BHR Pharma, ... global, Phase 3, multi-center pivotal trial ( www.synapse-trial.com ) ... product as a neuroprotective agent for treating severe traumatic brain injury ... will enroll approximately 1,200 patients with severe (Glasgow Coma Scale scores ...
Cached Medicine Technology:MitraClip(R) Therapy Introduced in Austria 2MitraClip(R) Therapy Introduced in Austria 3BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 2
(Date:8/21/2014)... News) -- Being born at a low birth weight puts ... new study suggests. The findings may partly explain high ... high prevalence of low birth weight, the researchers added. ... those with a low birth weight were 13 percent more ... normal birth weight. The risk of diabetes was 40 percent ...
(Date:8/21/2014)... 21, 2014 The W. Montague ... and a national voice in the elimination of ... disparities during the 112th National Medical Association’s (NMA) ... included: , John Ruffin, Ph.D, former Director of ... Disparities, whose life-long career and innovations have had ...
(Date:8/21/2014)... WA (PRWEB) August 21, 2014 ... Mulanax at Eastlake Chiropractic and Massage Center ... the Center’s growing team. Rina Lang, LMP and ... a wide range of massage techniques, and have developed ... settings. This is particularly important in a clinical ...
(Date:8/21/2014)... SAN FRANCISCO Aug. 21, 2014 Researchers in ... for congenital cataracts can quickly and accurately diagnose a ... to a study published online today in ... of Ophthalmology. Using a single test, doctors were ... based on their mutations reducing the time and money ...
(Date:8/21/2014)... August 21, 2014 The world wound ... billion in 2014 and reach USD 18.3 billion by ... period. The drivers of such growth include governments’ contribution ... and diabetic population, and surging ageing population. However, the ... wound care products. Region-wise, North America leads the global ...
Breaking Medicine News(10 mins):Health News:Low Birth Weights May Put Black Women at Risk for Diabetes 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3
... Home Workers in PA, MI, IL, FL, OH, MD, WI, WA Join Forces ... Private Equity ... Buyout, WASHINGTON, Oct. 3 ... workers union today,is launching a multi-state grassroots campaign calling on global buyout,giant the ...
... quit, researchers say , WEDNESDAY, Oct. 3 (HealthDay News) ... linked to nicotine dependence and to the anxiety and ... Scripps Research Institute in La Jolla, Calif., said the ... smokers kick the habit. , In rats, chronic nicotine ...
... 3 The following is a,statement of William ... President Bush today let down America,s children and ... legislation that would,increase the federal cigarette tax by ... Children,s Health Insurance Program (SCHIP). The President has ...
... Conn., Oct. 3 ,Unilens Vision Inc. (OTC Bulletin Board: ... that Eschenbach Optik has been named,the exclusive worldwide distributor ... Inc. will serve as the exclusive distributor,for North and ... be the,exclusive distributor in the rest of the world. ...
... and Revitalization, ORLANDO, Fla., Oct. 3 ... PRZ ), one of the nation,s leading providers,of ... issued,the following corporate update detailing recent developments that ... refined long term,growth strategy. Specifically, Lubinsky stated: ...
... Education Campaign Urges Enrollment, LOS ANGELES, Oct. 3 ... of clinical trials are being conducted to seek a,treatment, ... potentially fatal,autoimmune disease that affects more than 1.5 million ... key question that clinical trials answer is, "Will this ...
Cached Medicine News:Health News:SEIU Launches Multi-State Grassroots Campaign Calling on the Carlyle Group to Put Care Above Profits in Buyout of Nation's Largest Nursing Home Chain 2Health News:Rat Study Gets at Root of Nicotine Addiction 2Health News:President's Veto of Bill to Increase Cigarette Tax, Fund SCHIP Benefits Big Tobacco at Expense of America's Kids 2Health News:Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens 2Health News:Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens 3Health News:PainCare Reports on Key Corporate Developments 2Health News:PainCare Reports on Key Corporate Developments 3Health News:PainCare Reports on Key Corporate Developments 4Health News:PainCare Reports on Key Corporate Developments 5Health News:Clinical Trials for Lupus Underway After Decades of Drought 2
... Reichert TONO-PEN AVIA tonometer is an ... readings that correlate strongly with Goldmann ... ergonomic design and advanced electronic measurement ... fast and accurate IOP measurements with ...
... Delivery System is a ... to assemble brachytherapy seeds, ... into seed trains of ... variable seed to seed ...
... from innovative research in materials and technologies ... the aerospace and automotive industry, the high- ... footwear and textile industry. , ,This know-how ... Carrera sunglasses collection to create unique and ...
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Medicine Products: